Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives

A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis

(2019) Andrew J. Nunn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review

(2018) Emanuele Pontali et al.   EUROPEAN RESPIRATORY JOURNAL

Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study

(2018) Ying Zhao et al.   CLINICAL INFECTIOUS DISEASES

Whole Genome Sequencing of Mycobacterium tuberculosis

(2018) Andrea M. Cabibbe et al.   EUROPEAN RESPIRATORY JOURNAL

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

(2018) Nafees Ahmad et al.   LANCET

Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase

(2018) Matthew Ezewudo et al.   Scientific Reports

Evolution of programmatic definitions used in tuberculosis prevention and care

(2018) Giovanni Battista Migliori et al.   CLINICAL INFECTIOUS DISEASES

High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen

(2018) Norbert Ndjeka et al.   EUROPEAN RESPIRATORY JOURNAL

Introducing Molecular Testing of Pyrazinamide Susceptibility Improves MDR-TB Treatment Outcomes: A Prospective Cohort Study

(2018) Feng Sun et al.   EUROPEAN RESPIRATORY JOURNAL

QTc and anti-tuberculosis drugs: a perfect storm or a tempest in a teacup? Review of evidence and a risk assessment

(2018) I. Monedero-Recuero et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Global TB Network: working together to eliminate tuberculosis

(2018) Denise Rossato Silva et al.   Jornal Brasileiro de Pneumologia

Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study

(2018) Ndivhuho A Makhado et al.   LANCET INFECTIOUS DISEASES

Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence

(2017) Emanuele Pontali et al.   EUROPEAN RESPIRATORY JOURNAL

Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe

(2017) Marieke J. van der Werf et al.   EUROPEAN RESPIRATORY JOURNAL

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study

(2017) Sergey E. Borisov et al.   EUROPEAN RESPIRATORY JOURNAL

Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000–2015

(2017) Margareth Dalcolmo et al.   EUROPEAN RESPIRATORY JOURNAL

Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil

(2017) Margareth Dalcolmo et al.   EUROPEAN RESPIRATORY JOURNAL

World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update

(2017) Dennis Falzon et al.   EUROPEAN RESPIRATORY JOURNAL

Applicability of the shorter ‘Bangladesh regimen’ in high multidrug-resistant tuberculosis settings

(2017) Giovanni Sotgiu et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Multidrug-resistant TB in Eastern region of the EU: is the shorter regimen an exception or a rule?

(2017) Yanina Balabanova et al.   THORAX

Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide

(2017) Jean Claude Semuto Ngabonziza et al.   PLoS One

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project

(2016) Matteo Zignol et al.   LANCET INFECTIOUS DISEASES

Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis

(2014) M. L. Bastos et al.   CLINICAL INFECTIOUS DISEASES

A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment: TABLE 1

(2014) Akos Somoskovi et al.   EUROPEAN RESPIRATORY JOURNAL

Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients

(2014) K. J. M. Aung et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses

(2014) A. Piubello et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

(2011) D. Falzon et al.   EUROPEAN RESPIRATORY JOURNAL

Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis

(2010) Armand Van Deun et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE